Safety and Survival Outcomes of Lutetium-177-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study.
Kambiz RahbarMarkus EsslerKim M PabstMatthias EiberChristian Peter la FougèreVikas PrasadPhilipp RassekErgela HasaHelmut DittmannRalph A BundschuhWolfgang Peter FendlerMilena KurtineczAnja SchmallFrank VerholenAlton O SartorPublished in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2022)
Lu-PSMA is feasible and can be considered for future assessment of optimal treatment sequence.
Keyphrases